is tirzepatide for type 2 diabetes (Mounjaro): A Dual-Action Breakthrough and Weight Loss Lilly's Mounjaro tops other GLP-1s

A literature review

In clinical trials, 12%--18% of people taking Mounjaro and 25%--29% of people taking Zepbound reported nausea

Research Applications Type 2 diabetes treatment and glycemic control research Obesity management and substantial weight loss studies Dual incretin receptor agonism research Metabolic syndrome and insulin resistance studies Cardiovascular risk factor modification research Non-alcoholic fatty liver disease (NAFLD/NASH) studies Body composition and adipose tissue research Appetite regulation and energy balance studies Combination incretin therapy research Bariatric surgery alternative studies Lipid metabolism and dyslipidemia research Inflammatory marker reduction research Safety Profile Tirzepatide has been extensively evaluated for safety across multiple Phase III trials involving thousands of participants with exposure durations extending beyond two years

Many people allow their tirzepatide to warm slightly before injection to reduce discomfort

E., Vrooman H

Over time, as more manufacturers enter the market and competition increases, prices could gradually decrease further